A team of researchers from Italy conducted the study and published their findings in Breast Cancer Research and Treatment.<\/p>\n
The goal of their study was to \u201cassess the incidence and determinants\u201d of a reduction in early first-line SACT \u201cafter metastatic recurrence\u201d in TNBC that has been previously treated with neoadjuvant chemo-immunotherapy.<\/p>\n
The \u201cretrospective multicenter analysis\u201d consisted of 209 \u201cconsecutive\u201d patients who were diagnosed with early-stage TNBC and who underwent neoadjuvant chemo-immunotherapy. The median follow-up was 24 months, after which 54 patients \u201cdeveloped metastatic recurrence.\u201d<\/p>\n
For the purposes of the study, early first-line SACT attrition \u201cwas defined as failure to initiate [SACT] within 90 days of documented recurrence.\u201d Furthermore, investigators highlighted that univariate and multivariable logistic regression were used to analyze associations.<\/p>\n
Of the 54 patients who developed metastatic recurrence, 32.7% (n=17) experienced SACT attrition. The results revealed that \u201cpatients who did not initiate treatment had a significantly shorter disease-free interval compared to those who received first-line therapy (median 7.4 vs 14.3 months; P=0.011).\u201d<\/p>\n
Investigators also reported that among patients who experienced SACT attrition, \u201cPD-L1 positivity was more frequent\u201d (64.7%) and \u201ccentral nervous system metastases were more commonly observed\u201d (41.2%).<\/p>\n
Overall survival (OS) findings demonstrated that median OS \u201cfrom metastatic recurrence\u201d was 3.4 months and 12.4 months in the attrition and non-attrition cohorts, respectively. Results from the multivariable analysis showed that \u201cshorter disease-free interval (OR 0.87 per month; 95% CI 0.78-0.97), PD-L1 positivity (OR 8.73; 95% CI 1.81-42.04), and presence of central nervous system metastases (OR 7.09; 95% CI 1.41-35.57) were independently associated with early first-line therapeutic attrition.\u201d<\/p>\n
Investigators summarized the key takeaway of the real-world multicenter cohort study, which showed that \u201cnearly one-third of patients with TNBC experiencing metastatic recurrence after neoadjuvant chemo-immunotherapy did not initiate first-line systemic therapy within a clinically relevant timeframe.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"A team of researchers from Italy conducted the study and published their findings in Breast Cancer Research and…\n","protected":false},"author":2,"featured_media":583525,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-583524","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/583524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=583524"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/583524\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/583525"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=583524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=583524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=583524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}